<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02510677</url>
  </required_header>
  <id_info>
    <org_study_id>12-176</org_study_id>
    <nct_id>NCT02510677</nct_id>
  </id_info>
  <brief_title>Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT</brief_title>
  <acronym>FAST DOGS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of patients with heart failure has improved due to recent breakthrough in
      medical treatment and cardiac resynchronization devices. However, there is no paraclinical
      parameter to assess response to cardiac resynchronization therapy (CRT). This is a major
      issue since about a third of implanted patients will not be improved by CRT. CZT SPECT allows
      to perform myocardial perfusion imaging in less than 4 minutes and is able to study
      myocardial perfusion, viability, left ventricular function, but also ventricular asynchrony.

      Using low-dose dobutamine gated SPECT and CZT camera, we aimed to assess left ventricular
      dyssynchrony in viable segments in patients with heart failure eligible for CRT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measures of dyssynchrony parameters</measure>
    <time_frame>baseline</time_frame>
    <description>The primary endpoint is reproducible quantitative measures of dyssynchrony parameters between two successive acquisitions basal (entropy, bandwidth, standard deviation phase histogram).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>myocardial perfusion scintigraphy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>myocardial perfusion scintigraphy</intervention_name>
    <arm_group_label>myocardial perfusion scintigraphy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with heart failure on optimal medical therapy and targeted for cardiac
             resynchronization therapy according to current recommendations;

          -  Age over 18 years

          -  Clinically stable (without hospitalization for heart failure in the last month)

          -  Sinus rhythm

          -  Social security insurance

          -  Signed consent form

        Exclusion Criteria:

          -  Recent history (less than 21 days) of acute coronary syndrome or unstable angina;

          -  Recent history (less than 1 month) of acute heart failure;

          -  Right bundle branch block;

          -  Irregular heart rate;

          -  Double-chamber cardiac pacemaker

          -  Patients previously implanted with a single-chamber cardioverter-defibrillator must
             have at least 99 percent of unstimulated QRS.

          -  Countraindication to dobutamine therapy;

          -  Valvular heart disease, congenital heart disease, hypertrophic cardiomyopathy;

          -  Significant Ventricular arrhythmias;

          -  Hypertension (upper than 160/100 mmHg);

          -  Pregnant, breastfeeding or guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Médecine Nucléaire du CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2015</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

